Skip to main content
Journal cover image

Sirolimus monotherapy following Campath-1H induction.

Publication ,  Journal Article
Rao, V; Pirsch, JD; Becker, BN; Knechtle, SJ
Published in: Transplant Proc
May 2003

Sirolimus was used as a single agent for maintenance immunosuppression in a pilot trial of 29 primary kidney transplant patients using lymphocyte depletion with Campath-1H as an induction strategy. This allowed sirolimus to be analyzed (dose, blood level, and side effect profile) in the absence of steroid and calcineurin inhibitors. A sirolimus dose of 4 mg/day resulted in blood levels in the 8 to 9 ng/mL range. Of the 29 patients, 8 patients (28%) had rejection. The sirolimus levels were not significantly different in patients with or without rejection. The cardiovascular risk profile in terms of lipid profile and hypertension control was favorable. Increase in cholesterol and triglyceride levels at one month (not statistically significant) necessitated treatment in 60% of patients with decline in levels by 6 and 12 months. Management of hypertension was also favorable with the majority of patients (55%) being on one hypertensive medication. Sirolimus monotherapy was well tolerated on the whole. Wound healing, leukopenia, and anemia were not significant problems. In conclusion, monotherapy has been well tolerated with a favorable side effect profile. However, a rejection rate of 28% was noted.

Duke Scholars

Published In

Transplant Proc

DOI

ISSN

0041-1345

Publication Date

May 2003

Volume

35

Issue

3 Suppl

Start / End Page

128S / 130S

Location

United States

Related Subject Headings

  • Time Factors
  • Sirolimus
  • Postoperative Complications
  • Platelet Count
  • Monitoring, Physiologic
  • Leukopenia
  • Leukocyte Count
  • Kidney Transplantation
  • Immunosuppressive Agents
  • Hypolipidemic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rao, V., Pirsch, J. D., Becker, B. N., & Knechtle, S. J. (2003). Sirolimus monotherapy following Campath-1H induction. Transplant Proc, 35(3 Suppl), 128S-130S. https://doi.org/10.1016/s0041-1345(03)00227-6
Rao, V., J. D. Pirsch, B. N. Becker, and S. J. Knechtle. “Sirolimus monotherapy following Campath-1H induction.Transplant Proc 35, no. 3 Suppl (May 2003): 128S-130S. https://doi.org/10.1016/s0041-1345(03)00227-6.
Rao V, Pirsch JD, Becker BN, Knechtle SJ. Sirolimus monotherapy following Campath-1H induction. Transplant Proc. 2003 May;35(3 Suppl):128S-130S.
Rao, V., et al. “Sirolimus monotherapy following Campath-1H induction.Transplant Proc, vol. 35, no. 3 Suppl, May 2003, pp. 128S-130S. Pubmed, doi:10.1016/s0041-1345(03)00227-6.
Rao V, Pirsch JD, Becker BN, Knechtle SJ. Sirolimus monotherapy following Campath-1H induction. Transplant Proc. 2003 May;35(3 Suppl):128S-130S.
Journal cover image

Published In

Transplant Proc

DOI

ISSN

0041-1345

Publication Date

May 2003

Volume

35

Issue

3 Suppl

Start / End Page

128S / 130S

Location

United States

Related Subject Headings

  • Time Factors
  • Sirolimus
  • Postoperative Complications
  • Platelet Count
  • Monitoring, Physiologic
  • Leukopenia
  • Leukocyte Count
  • Kidney Transplantation
  • Immunosuppressive Agents
  • Hypolipidemic Agents